Cargando…
A phase 1 ‘window-of-opportunity’ trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patients
BACKGROUND: Neo-adjuvant chemoradiotherapy followed by surgery is the standard treatment with curative intent for oesophageal cancer patients, with 5-year overall survival rates up to 50 %. However, patients’ quality of life is severely compromised by oesophagectomy, and eventually many patients die...
Autores principales: | Larue, Ruben T. H. M., Van De Voorde, Lien, Berbée, Maaike, van Elmpt, Wouter J. C., Dubois, Ludwig J., Panth, Kranthi M., Peeters, Sarah G. J. A., Claessens, Ann, Schreurs, Wendy M. J., Nap, Marius, Warmerdam, Fabiënne A. R. M., Erdkamp, Frans L. G., Sosef, Meindert N., Lambin, Philippe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4989456/ https://www.ncbi.nlm.nih.gov/pubmed/27535748 http://dx.doi.org/10.1186/s12885-016-2709-z |
Ejemplares similares
-
Efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in nasopharyngeal carcinoma in vitro and in vivo
por: Huang, Yan, et al.
Publicado: (2018) -
Anticancer efficacy of the hypoxia‐activated prodrug evofosfamide (TH‐302) in osteolytic breast cancer murine models
por: Liapis, Vasilios, et al.
Publicado: (2016) -
Lymph node response to chemoradiotherapy in oesophageal cancer patients: relationship with radiotherapy fields
por: Koemans, Willem J., et al.
Publicado: (2020) -
Hypoxia Imaging With PET Correlates With Antitumor Activity of the Hypoxia-Activated Prodrug Evofosfamide (TH-302) in Rodent Glioma Models
por: Stokes, Ashley M., et al.
Publicado: (2016) -
An Intratumor Pharmacokinetic/Pharmacodynamic Model for the Hypoxia-Activated Prodrug Evofosfamide (TH-302): Monotherapy Activity is Not Dependent on a Bystander Effect()()
por: Hong, Cho Rong, et al.
Publicado: (2018)